DCAT Debrief: Lonza’s perspective on pharma’s path forward with AI and drug development

In a recent discussion with Jan Vertommen, vice president and head of commercial development for the small molecules division at Lonza, key insights were shared regarding the pharmaceutical industry’s current landscape and future trajectory.